Pharmacotherapy for Attention-deficit–Hyperactivity Disorder

Stephen V Faraone, Michael Pucci, David Coghill
US Psychiatry, 2009;2(1):17-28
pdf icon download pdf ejournal view ejournal

Abstract

Attention-deficit–hyperactivity disorder (ADHD), one of the most common psychiatric disorders worldwide, is characterized by developmentally inappropriate levels of inattention and/or hyperactivity–impulsivity. Pharmacotherapy is an important treatment option for ADHD, either on its own or in combination with behavioral, educational, and family interventions. Although stimulants are the most widely prescribed medications for ADHD, with numerous studies demonstrating their efficacy and safety in children, adolescents, and adults, there are other agents that have been shown to be effective and that can be useful when stimulants are not indicated. Differences exist between Europe and North America in terms of the availability of pharmacological agents, guidelines for the use of drugs, and perceptions about therapeutic options. This article describes the pharmacological and clinical characteristics of different medications approved globally for the treatment of ADHD and the factors that contribute to varying treatment choices, therapeutic options, and perceptions about ADHD in Europe and North America.
Keywords
Attention-deficit–hyperactivity disorder (ADHD), stimulants, children, adults, pharmacotherapy
Disclosure This article was supported by funding from Shire Development Inc.
Received: October 20, 2008 Accepted November 28, 2008
Correspondence: Stephen V Farone, PhD, Department of Psychiatry, State University of New York, Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210. E: farone@upstate.edu

Attention-deficit–hyperactivity disorder (ADHD), one of the most common psychiatric disorders worldwide, is characterised by developmentally inappropriate levels of hyperactivity–impulsivity and/or inattention.1 ADHD has been estimated to affect 5–12% of children worldwide,2–4 with approximately 30–70% of those with ADHD in childhood showing persistence of ADHD symptoms into adolescence5,6 and up to 66% into adulthood.6–10 Children diagnosed with ADHD are impaired across a number of major domains, including their functioning at school, at home and with their peers.11 School-based impairments include lower than expected or erratic grades, poor organisational and study skills, difficulty in test taking and failure to complete homework.11 Children with ADHD perform less effectively in school than unaffected children in that they achieve poorer grades in academic subjects, have to repeat school grades more frequently, have more special educational placements and require more out-of-class tutoring.12 The behavioural difficulties associated with ADHD include continuous friction with peers, parents and teachers, often leading to placement in special classes, suspension and/or expulsion,13 and social rejection by their peers due to aggression, impulsivity and non-compliance with rules.14 As they grow up, children with ADHD become disproportionately involved in the consumption of cigarettes, alcohol and illicit drugs, and appear to maintain their risk of continued addictions later in life.15

Adults diagnosed with ADHD may still be hyperactive, impulsive or inattentive, but their symptoms usually manifest in different ways from children.16 Symptom-wise, adults with ADHD often show overt hyperactivity symptoms less frequently than inattention-based symptoms; however, as in children, adults with ADHD experience significant impairments across several domains.17–20 These include immaturity, social maladjustment, higher rates of separation and divorce, fewer years of education, lower socioeconomic status, lower occupational achievement, lower rates of professional employment, increased work difficulties, poor work performance, more frequent changes in employment and higher rates of quitting or being fired from jobs.18,21

References:
  1. American Psychiatric Association, Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. Fourth Edition. Text Revision, Washington, DC: American Psychiatric Association; 2000:85–93.
  2. Biederman J, Faraone SV, Attention-deficit hyperactivity disorder, Lancet, 2005;366(9481):237–48.
  3. Polanczyk G, de Lima MS, Horta BL, et al., The worldwide prevalence of ADHD: a systematic review and metaregression analysis, Am J Psychiatry, 2007;164(6): 942–8.
  4. Faraone SV, Sergeant J, Gillberg C, Biederman J, The worldwide prevalence of ADHD: is it an American condition?, World Psychiatry, 2003;2(2):104–13.
  5. Barkley RA, Fischer M, Edelbrock CS, Smallish L, The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study, J Am Acad Child Adolesc Psychiatry, 1990;29(4):546–57.
  6. Barkley RA, Fischer M, Smallish L, Fletcher K, The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder, J Abnorm Psychol, 2002;111(2): 279–89.
  7. Weiss MD, Weiss JR, A guide to the treatment of adults with ADHD, J Clin Psychiatry, 2004;65(Suppl. 3):27–37.
  8. Zametkin AJ, Ernst M, Problems in the management of attention-deficit-hyperactivity disorder, N Engl J Med, 1999;340(1):40–46.
  9. Faraone SV, Biederman J, Mick E, The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies, Psychol Med, 2006;36(2):159–65.
  10. Biederman J, Monuteaux MC, Mick E, et al., Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study, Psychol Med, 2006;36(2):167–79.
  11. Dulcan M, and the Work Group on Quality Issues, Practice parameters for the assessment and treatment of children, adolescents, and adults with attentiondeficit/ hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 1997;36(Suppl. 10):85–121S.
  12. Spencer TJ, Biederman J, Mick E, Attention deficit hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology, J Pediatr Psychol, 2007;32(6):631–42.
  13. Faraone SV, Biederman J, Lehman BK, et al., Intellectual performance and school failure in children with attention deficit hyperactivity disorder and in their siblings, J Abnorm Psychol, 1993;102(4):616–23.
  14. Erhardt D, Hinshaw SP, Initial sociometric impressions of attention-deficit hyperactivity disorder and comparison boys: predictions from social behaviors and from nonbehavioral variables, J Consult Clin Psychol, 1994;62(4): 833–42.
  15. Biederman J, Wilens TE, Mick E, et al., Does attentiondeficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence?, Biol Psychiatry, 1998;44(4):269–73.
  16. Biederman J, Mick E, Faraone SV, Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type, Am J Psychiatry, 2000;157(5):816–18.
  17. Faraone SV, Spencer TJ, Montano CB, Biederman J, Attention deficit hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care, Arch Intern Med, 2004;164(11):1221–6.
  18. Biederman J, Faraone SV, Spencer TJ, et al., Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community, J Clin Psychiatry, 2006;67(4):524–40.
  19. Lamberg L, ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life, JAMA, 2003;290(12):1565–7.
  20. Adler LA, Chua HC, Management of ADHD in adults, J Clin Psychiatry, 2002;63(Suppl. 12):29–35.
  21. Adler L, Cohen J, Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder, Psychiatr Clin North Am, 2004;27(2):187–201.
  22. De Graaf R, Kessler RC, Fayyad J, et al., The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: Results from the WHO World Mental Health Survey Initiative, Occup Environ Med, 2008;65:835–42.
  23. Barkley RA, Guevremont DC, Anastopoulos AD, et al., Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a three- to five-year follow-up survey, Pediatrics, 1993;92(2):212–18.
  24. Secnik K, Swensen A, Lage MJ, Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder, Pharmacoeconomics, 2005;23(1): 93–102.
  25. Barkley R, Comorbid psychiatric disorders and psychological maladjustment. In: Barkley RA, Murphy KR, Fisher M (eds), ADHD in Adults: What Does the Science Tell Us? New York, NY: Guilford Press, 2009; in press.
  26. Faraone SV, Biederman J, Spencer TJ, Comparing the efficacy of medications for ADHD using meta-analysis, Med Gen Med, 2006;8(4):4.
  27. Faraone SV, Spencer T, Aleardi M, et al., Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder, J Clin Psychopharmacol, 2004;24(1):24–9.
  28. Banaschewski T, Coghill D, Santosh P, et al., Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline, Eur Child Adolesc Psychiatry, 2006;15(8):476–95.
  29. Markowitz JS, Straughn AB, Patrick KS, Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations, Pharmacotherapy, 2003;23(10):1281–99.
  30. Arnold LE, Methylphenidate versus amphetamine: comparative review, J Atten Disord, 2000;3(4):200–211.
  31. Faraone SV, Understanding the effect size of ADHD medications: implications for clinical care, 2008. Available at: www.medscape.com/viewarticle/461543
  32. Faraone SV, Understanding effect size: how it’s measured and what it means, 2008. Available at: www.medscape.com/viewarticle/569729
  33. Barkley RA, McMurray MB, Edelbrock CS, Robbins K, Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebocontrolled evaluation, Pediatrics, 1990;86(2):184–92.
  34. Ahmann PA, Waltonen SJ, Olson KA, et al., Placebocontrolled evaluation of Ritalin side effects, Pediatrics, 1993;91(6):1101–6.
  35. Schachar RJ, Tannock R, Cunningham C, Corkum PV, Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate, J Am Acad Child Adolesc Psychiatry, 1997;36(6):754–63.
  36. Charach A, Ickowicz A, Schachar R, Stimulant treatment over five years: adherence, effectiveness, and adverse effects, J Am Acad Child Adolesc Psychiatry, 2004;43(5): 559–67.
  37. Gillberg C, Melander H, von Knorring AL, et al., Longterm stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial, Arch Gen Psychiatry, 1997;54(9):857–64.
  38. Efron D, Jarman F, Barker M, Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, cross-over trial, Pediatrics, 1997;100(4):662–6.
  39. Spencer T, Biederman J, Wilens T, et al., Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder, Arch Gen Psychiatry, 2001;58(8):775–82.
  40. Wolraich ML, Greenhill LL, Pelham W, et al., Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder, Pediatrics, 2001;108(4):883–92.
  41. Steele M, Weiss M, Swanson J, et al., A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder, Can J Clin Pharmacol, 2006;13(1):e50–62.
  42. Greenhill LL, Findling RL, Swanson JM, A double-blind, placebo-controlled study of modified-release methylphenidate in children with attentiondeficit/ hyperactivity disorder, Pediatrics, 2002;109(3):E39.
  43. Findling RL, Quinn D, Hatch SJ, et al., Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder, Eur Child Adolesc Psychiatry, 2006;15(8):450–59.
  44. Greenhill LL, Muniz R, Ball RR, et al., Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 2006;45(7):817–23.
  45. Findling RL, Bukstein OG, Melmed RD, et al., A randomized, double-blind, placebo-controlled, parallelgroup study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder, J Clin Psychiatry, 2008;69(1):149–59.
  46. McGough JJ, Biederman J, Wigal SB, et al., Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD, J Am Acad Child Adolesc Psychiatry, 2005;44(6):530–38.
  47. Biederman J, Krishnan S, Zhang Y, et al., Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forceddose, parallel-group study, Clin Ther, 2007;29(3):450–63.
  48. Graham J, Coghill D, Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management, CNS Drugs, 2008;22(3):213–37.
  49. Mick E, Biederman J, Jetton J, Faraone SV, Sleep disturbances associated with attention deficit hyperactivity disorder: the impact of psychiatric comorbidity and pharmacotherapy, J Child Adolesc Psychopharmacol, 2000;10(3):223–31.
  50. Stein MA, Unravelling sleep problems in treated and untreated children with ADHD, J Child Adolesc Psychopharmacol, 1999;9(3):157–68.
  51. Pliszka S, Practice parameter for the assessment and treatment of children and adolescents with attentiondeficit/ hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 2007;46(7):894–921.
  52. Adler LA, Goodman DW, Kollins SH, et al., on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder, J Clin Psychiatry, 2008;69(9):1364–73.
  53. Rappley MD, Moore JW, Dokken D, ADHD drugs and cardiovascular risk, N Engl J Med, 2006;354(21):2296–8.
  54. Rapport MD, Moffitt C, Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects, Clin Psychol Rev, 2002;22(8):1107–31.
  55. Findling RL, Biederman J, Wilens TE, et al., Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children, J Pediatr, 2005;147(3): 348–54.
  56. Wilens TE, Hammerness PG, Biederman J, et al., Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder, J Clin Psychiatry, 2005;66(2):253–9.
  57. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Longterm cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD, CNS Spectr, 2005;10(Suppl. 20)(12):35–43.
  58. Concerta (methylphenidate hydrochloride) Extendedrelease Tablets Briefing Document. FDA PAC March 06. McNeil Specialty Pharmaceuticals, 2008. Available at: www.fda.gov/ohrms/dockets/ac/06/briefing/2006- 4210b_14_McNeil%20FDA%20PAC%20March%2006%20 Briefing%20Document.pdf
  59. Harpin VA, Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006, Arch Dis Child Educ Pract Ed, 2008;93(2):58–65.
  60. White WB, Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension, Am J Hypertens, 1999;12(apt. 2):50–55S.
  61. Poulton A, Growth on stimulant medication; clarifying the confusion: a review, Arch Dis Child, 2005;90(8):801–6.
  62. Faraone SV, Biederman J, Morley CP, Spencer TJ, Effect of stimulants on height and weight: a review of the literature, J Am Acad Child Adolesc Psychiatry, 2008;47(9): 994–1009.
  63. Faraone SV, Biederman J, Monuteaux M, Spencer T, Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/ hyperactivity disorder on growth, J Child Adolesc Psychopharmacol, 2005;15(2):191–202.
  64. Spencer TJ, Faraone SV, Biederman J, et al., Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?, J Am Acad Child Adolesc Psychiatry, 2006;45(5):527–37.
  65. Faraone SV, Giefer EE, Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth, J Am Acad Child Adolesc Psychiatry, 2007;46(9):1138–47.
  66. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update, Endocr Pract, 2003;9(1):64–76.
  67. Safer DJ, Allen RP, Barr E, Growth rebound after termination of stimulant drugs, J Pediatr, 1975;86(1): 113–16.
  68. Satterfield JH, Cantwell DP, Schell A, Blaschke T, Growth of hyperactive children treated with methylphenidate, Arch Gen Psychiatry, 1979;36(2):212–17.
  69. Safer DJ, Allen RP, Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children, Pediatrics, 1973;51(4):660–67.
  70. James A, Lai FH, Dahl C, Attention deficit hyperactivity disorder and suicide: a review of possible associations, Acta Psychiatr Scand, 2004;110(6):408–15.
  71. Biederman J, Ball SW, Monuteaux MC, et al., New insights into the comorbidity between ADHD and major depression in adolescent and young adult females, J Am Acad Child Adolesc Psychiatry, 2008;47(4):426–34.
  72. Faraone SV, Wilens T, Effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion, J Clin Psychiatry, 2007;68:(Suppl. 11)15–22.
  73. Kollins SH, Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD), Am J Addict, 2007;16(Suppl. 1):35–42.
  74. Lambert NM, Hartsough CS, Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants, J Learn Disabil, 1998;31(6):533–44.
  75. Biederman J, Wilens T, Mick E, et al., Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder, Pediatrics, 1999;104(2):e20.
  76. Wilens TE, Faraone SV, Biederman J, Gunawardene S, Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature, Pediatrics, 2003;111(1):179–85.
  77. Greenhill LL, Pliszka S, Dulcan MK, et al., Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults, J Am Acad Child Adolesc Psychiatry, 2002;41(Suppl. 2):26–49S.
  78. Carlson GA, Kelly KL, Stimulant rebound: how common is it and what does it mean?, J Child Adolesc Psychopharmacol, 2003;13(2):137–42.
  79. Efron D, Jarman F, Barker M, Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial, Pediatrics, 1997;100(6):E6.
  80. Paterson R, Douglas C, Hallmayer J, et al., A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder, Aust N Z J Psychiatry, 1999;33(4): 494–502.
  81. Weiss M, Hechtman L, The Adult ADHD Research Group, A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults, J Clin Psychiatry, 2006;67(4):611–19.
  82. Taylor FB, Russo J, Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults, J Child Adolesc Psychopharmacol, 2000;10(4):311–20.
  83. Taylor FB, Russo J, Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder, J Clin Psychopharmacol, 2001;21(2):223–8.
  84. Swanson JM, Wigal S, Greenhill LL, et al., Analog classroom assessment of Adderall® in children with ADHD, J Am Acad Child Adolesc Psychiatry, 1998;37(5):519–26.
  85. James RS, Sharp WS, Bastain TM, et al., Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD, J Am Acad Child Adolesc Psychiatry, 2001;40(11):1268–76.
  86. Faraone SV, Biederman J, Roe C, Comparative efficacy of Adderall and methylphe idate in attention-deficit/ hyperactivity disorder: a meta-analysis, J Clin Psychopharmacol, 2002;22(5):468–73.
  87. Wilens TE, Drug therapy for adults with attention-deficit hyperactivity disorder, Drugs, 2003;63(22):2395–2411.
  88. Horrigan JP, Barnhill LJ, Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder, J Clin Psychiatry, 2000;61(6):414–17.
  89. Biederman J, Lopez FA, Boellner SW, Chandler MC, A randomized, double-blind, placebo-controlled, parallelgroup study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder, Pediatrics, 2002;110(2 Pt 1):258–66.
  90. Weisler RH, Biederman J, Spencer TJ, et al., on behalf of the SLI381.303 Study Group, Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial, CNS Spectr, 2006;11(8): 625–39.
  91. Biederman J, Boellner SW, Childress A, et al., Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a doubleblind, placebo-controlled, crossover analog classroom study, Biol Psychiatry, 2007;62(9):970–76.
  92. Biederman J, Spencer TJ, Wilens TE, et al., Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD, CNS Spectr, 2005;10(12 Suppl. 20):16–25.
  93. Wolraich ML, Doffing MA, Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate, CNS Drugs, 2004;18(4):243–50.
  94. Greenhill LL, Halperin JM, Abikoff H, Stimulant medications, J Am Acad Child Adolesc Psychiatry, 1999;38(5): 503–12.
  95. Kooij JJ, Burger H, Boonstra AM, et al., Efficacy and safety of methylphenidate in 45 adults with attentiondeficit/ hyperactivity disorder. A randomized placebocontrolled double-blind cross-over trial, Psychol Med, 2004;34(6):973–82.
  96. Keating GM, Figgitt DP, Dexmethylphenidate, Drugs, 2002;62(13):1899–1904.
  97. Pelham WE, Gnagy EM, Burrows-Maclean L, et al., Oncea- day Concerta methylphenidate versus three-timesdaily methylphenidate in laboratory and natural settings, Pharmacotherapy for Attention-deficit–Hyperactivity Disorder E UPediatrics, 2001;107(6):E105.
  98. Newcorn JH, Kratochvil CJ, Allen AJ, et al., Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response, Am J Psychiatry, 2008;165(6):721–30.
  99. Biederman J, Mick E, Surman C, et al., A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder, Biol Psychiatry, 2006;59(9):829–35.
  100. Döpfner M, Gerber WD, Banaschewski T, et al., Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting, Eur Child Adolesc Psychiatry, 2004;13(Suppl. 1): I93–101.
  101. Spencer TJ, Adler LA, McGough JJ, et al., Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder, Biol Psychiatry, 2007;61(12):1380–87.
  102. Stanczak A, Ferra A, Prodrugs and soft drugs, Pharmacol Rep, 2006;58(5):599–613.
  103. Weisler RH, Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder, Expert Opin Pharmacother, 2007;8(6):745–58.
  104. Jasinski D, Krishnan S, Abuse liability and safety of oral lisdexamphetamine dimesylak in individuals with a history of stimulant abuse, J Psychopharmacol, 2009;23: 41–18.
  105. Jasinski DR, Krishnan S, Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers, J Psychopharmacol, 2009;23: 410–18.
  106. Findling RL, Childress AC, Krishnan S, McGough JJ, Longterm effectiveness and safety of lisdexamfetamine dimesylate in school-age children with attentiondeficit/ hyperactivity disorder, CNS Spectr, 2008;13(7): 614–20.
  107. Findling RL, Childress AC, Krishnan S, McGough JJ, Long-term efficacy and safety of lisdexamfetamine in school-age children with attention-deficit/hyperactivity disorder. Poster presented at: 160th Annual Meeting of the American Psychiatric Association, 2007.
  108. Silva R, Muniz R, Pestreich LK, Brams M, et al., Efficacy of two long-acting methylphenidate formulations in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting, J Child Adolesc Psychopharmacol, 2005;15(4):637–54.
  109. Swanson JM, Wigal SB, Wigal T, et al., and the COMACS Study Group, A comparison of once-daily extendedrelease methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The Comacs Study), Pediatrics, 2004;113(3 Pt 1): e206–16.
  110. Silva RR, Muniz R, Pestreich L, et al., Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/ hyperactivity disorder, J Child Adolesc Psychopharmacol, 2006;16(3):239–51.
  111. Brams M, Muniz R, Childress A, et al., A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect, CNS Drugs, 2008;22(8):693–704.
  112. Wilens TE, Boellner SW, López FA, et al., Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 2008;47(6):700–708.
  113. McGough JJ, Wigal SB, Abikoff H, et al., A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD, J Atten Disord, 2006;9(3):476–85.
  114. Wigal SB, Kollins SH, Squires LA, Childress AC, Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attentiondeficit/ hyperactivity disorder. Abstract presented at: The American Academy of Child & Adolescent Psychiatry’s 55th Annual Meeting, 2008.
  115. Michelson D, Faries D, Wernicke J, et al., Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study, Pediatrics, 2001;108(5):E83.
  116. Kelsey DK, Sumner CR, Casat CD, et al., Once-daily atomoxetine treatment for children with attentiondeficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial, Pediatrics, 2004;114(1):e1–8.
  117. Rappley MD, Clinical practice. Attention deficithyperactivity disorder, N Engl J Med, 2005;352(2):165–73.
  118. Gibson AP, Bettinger TL, Patel NC, Crismon ML, Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder, Ann Pharmacother, 2006;40(6):1134–42.
  119. Prasad S, Steer C, Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence, Paediatr Drugs, 2008;10(1):39–47.
  120. Buitelaar JK, Danckaerts M, Gillberg C, et al., A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD, Eur Child Adolesc Psychiatry, 2004;13(4):249–57.
  121. Banaschewski T, Roessner V, Dittmann RW, et al., Nonstimulant medications in the treatment of ADHD, Eur Child Adolesc Psychiatry, 2004;13(Suppl. 1):102–16.
  122. Adler LA, Spencer TJ, Milton DR, et al., Long-term, openlabel study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis, J Clin Psychiatry, 2005;66(3):294–9.
  123. Pliszka SR, Crismon ML, Hughes CW, et al., The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder: The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attentiondeficit/ hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 2006;45(6):642–57.
  124. Heil SH, Holmes HW, Bickel WK, et al., Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users, Drug Alcohol Depend, 2002;67(2):149–56.
  125. Himpel S, Banaschewski T, Heise CA, Rothenberger A, The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder, Expert Opin Drug Saf, 2005;4(2):311–21.
  126. Wernicke JF, Faries D, Girod D, et al., Cardiovascular effects of atomoxetine in children, adolescents, and adults, Drug Saf, 2003;26(10):729–40.
  127. Connor DF, Fletcher KE, Swanson JM, A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 1999;38(12): 1551–9.
  128. Biederman J, Spencer T, Non-stimulant treatments for ADHD, Eur Child Adolesc Psychiatry, 2000;9(Suppl. 1):I51–9.
  129. Palumbo DR, Sallee FR, Pelham WE Jr., Bukstein OG, Daviss WB, McDermott MP, Clonidine for attention deficit/hyperactivity disorder, Efficacy and tolerability outcomes, J Am Acad Child Adolesc Psychiatry, 2008;47(2): 180–88.
  130. Scahill L, Chappell PB, Kim YS, et al., A placebocontrolled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder, Am J Psychiatry, 2001;158(7): 1067–74.
  131. Chappell PB, Riddle MA, Scahill L, et al., Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience, J Am Acad Child Adolesc Psychiatry, 1995;34(9): 1140–46.
  132. Hunt RD, Arnsten AFT, Asbell MD, An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 1995;34(1):50-54.
  133. Horrigan JP, Barnhill LJ, Guanfacine for treatment of attention-deficit hyperactivity disorder in boys, J Child Adolesc Psychopharmacol, 1995;5:215–23.
  134. Biederman J, Melmed RD, Patel A, et al, for the SPD503 Study Group. A randomized, double-blind, placebocontrolled study of guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder, Pediatrics, 2008;121(1):e73–84.
  135. Sallee F, McGough J, Wigal T, et al., for the SPD503 Study Group. Guanfacine rxtended telease in children and adolescents with attention-deficit–hyperactivity disorder: a placebo-controlled trial, J Am Acad Child Adolesc Psychiatry, 2009; in press.
  136. Biederman J, Baldessarini RJ, Wright V, et al., A doubleblind placebo controlled study of desipramine in the treatment of ADHD: I. Efficacy, J Am Acad Child Adolesc Psychiatry, 1989;28(5):777–84.
  137. Wilens TE, Biederman J, Prince J, et al., Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder, Am J Psychiatry, 1996;153(9):1147–53.
  138. Wilens TE, Biederman J, Baldessarini RJ, et al., Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents, J Am Acad Child Adolesc Psychiatry, 1996;35(11):1491–1501.
  139. Conners CK, Casat CD, Gualtieri CT, et al., Bupropion hydrochloride in attention deficit disorder with hyperactivity, J Am Acad Child Adolesc Psychiatry, 1996;35(10):1314–21.
  140. Barrickman LL, Perry PJ, Allen AJ, et al., Bupropion versus methylphenidate in the treatment of attentiondeficit hyperactivity disorder, J Am Acad Child Adolesc Psychiatry, 1995;34(5):649–57.
  141. López FA, ADHD: new pharmacological treatments on the horizon, J Dev Behav Pediatr, 2006;27(5):410–16.
  142. MTA Cooperative Group, A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD, Arch Gen Psychiatry, 1999;56(12):1073–86.
  143. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ, Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention, Eur Neuropsychopharmacol, 2003;13(4):297–304.
  144. Buitelaar JK, Barton J, Danckaerts M, et al., A comparison of North American versus non-North American ADHD study populations, Eur Child Adolesc Psychiatry, 2006;15(3): 177–81.
  145. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement, Clinical practice guideline: treatment of the school-aged child with attentiondeficit/ hyperactivity disorder, Pediatrics, 2001;108(4):1033–44.
  146. Dalsgaard S, Hansen N, Mortensen PB, et al., Reassessment of ADHD in a historical cohort of children treated with stimulants in the period 1969–1989, Eur Child Adolesc Psychiatry, 2001;10(4):230–39.
  147. Taylor E, Dopfner M, Sergeant J, et al., European clinical guidelines for hyperkinetic disorder-first upgrade, Eur Child Adolesc Psychiatry, 2004;13(Suppl. 1:)I7–I30.
  148. Lee SI, Schachar RJ, Chen SX, et al., Predictive validity of DSM-IV and ICD-10 criteria for ADHD and hyperkinetic disorder, J Child Psychol Psychiatry, 2008;49(1):70–78.
  149. Remschmidt H, Global consensus on ADHD/HKD, Eur Child Adolesc Psychiatry, 2005;14(3):127–37.
  150. National Institute for Health and Clinical Excellence, Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. NICE Clinical Guideline 72. Uncorrected Proof, 2008. Avilable at: www.nice.org.uk/nicemedia/pdf/CG72 FullGuideline.pdf
  151. Griffiths P, Mravcik V, Lopez D, Klempova D, Quite a lot of smoke but very limited fire-the use of methamphetamine in Europe, Drug Alcohol Rev, 2008;27(3):236–42.
  152. Wilens TE, Dodson W, A clinical perspective of attention-deficit/hyperactivity disorder into adulthood, J Clin Psychiatry, 2004;65(10):1301–13.
close

This content is copyright protected

However, if you would like to share the information on this webpage, you may use the headline and link below:

Pharmacotherapy for Attention-deficit–Hyperactivity Disorder

Read more: Pharmacotherapy for Attention-deficit–Hyperactivity Disorder